{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:56:38Z","timestamp":1793422598837,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"am","delay-in-days":387,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008644","name":"Japan Diabetes Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008644","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009954","name":"Taiho Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009954","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.beem.2022.101657","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T21:37:25Z","timestamp":1648762645000},"page":"101657","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Type 1 diabetes related to immune checkpoint inhibitors"],"prefix":"10.1016","volume":"36","author":[{"given":"Megumi","family":"Tachibana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihisa","family":"Imagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2022.101657_bib1","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.beem.2022.101657_bib2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.7861\/clinmed.2020-0054","article-title":"Is immune checkpoint inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus?","volume":"20","author":"Kyriacou","year":"2020","journal-title":"Clin Med"},{"key":"10.1016\/j.beem.2022.101657_bib3","first-page":"232","article-title":"Diabetes and blood glucose disorders under anti-PD1","volume":"41","author":"Magis","year":"2018","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.beem.2022.101657_bib4","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.2337\/diacare.26.8.2345","article-title":"Fulminant type 1 diabetes: a nationwide survey in Japan","volume":"26","author":"Imagawa","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.beem.2022.101657_bib5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/ncpendmet0351","article-title":"Fulminant type 1 diabetes: a novel clinical entity requiring special attention by all medical practitioners","volume":"3","author":"Hanafusa","year":"2007","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101657_bib6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s13340-012-0098-3","article-title":"Report of the committee of the Japan Diabetes Society on the Research of Fulminant and Acute-onset type 1 diabetes mellitus: new diagnostic criteria of fulminant type 1 diabetes mellitus","volume":"3","author":"Imagawa","year":"2012","journal-title":"Diabetol Int"},{"key":"10.1016\/j.beem.2022.101657_bib7","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/intimm\/dxm057","article-title":"PD-1 and PD-1 ligands: from discovery to clinical application","volume":"19","author":"Okazaki","year":"2007","journal-title":"Int Immunol"},{"key":"10.1016\/j.beem.2022.101657_bib8","doi-asserted-by":"crossref","first-page":"11823","DOI":"10.1073\/pnas.0505497102","article-title":"Establishment of NOD-Pdcd1\u2212\/\u2212 mice as an efficient animal model of type I diabetes","volume":"102","author":"Wang","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beem.2022.101657_bib9","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/cei.12603","article-title":"Low programmed cell death-1 (PD-1) expression in peripheral CD4(+) T cells in Japanese patients with autoimmune type 1 diabetes","volume":"180","author":"Fujisawa","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.beem.2022.101657_bib10","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3389\/fendo.2020.00569","article-title":"Role of the PD-1\/PD-L1 Dyad in the maintenance of pancreatic immune tolerance for prevention of type 1 diabetes","volume":"11","author":"Falcone","year":"2020","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.beem.2022.101657_bib11","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.31557\/APJCP.2020.21.6.1697","article-title":"Predictors of the onset of Type 1 diabetes obtained from real-world data analysis in cancer patients treated with immune checkpoint inhibitors","volume":"21","author":"Takada","year":"2020","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.beem.2022.101657_bib12","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s13340-018-0362-2","article-title":"Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy","volume":"10","author":"Baden","year":"2019","journal-title":"Diabetol Int"},{"key":"10.1016\/j.beem.2022.101657_bib13","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s11154-020-09618-w","article-title":"Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literature","volume":"22","author":"Lo Preiato","year":"2021","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.beem.2022.101657_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2018-000591","article-title":"Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes","volume":"7","author":"Kotwal","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.beem.2022.101657_bib15","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.beem.2022.101657_bib16","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.2169\/internalmedicine.2780-19","article-title":"A\u00a0patient with nivolumab-related fulminant type 1 diabetes mellitus whose serum C-peptide level was preserved at the initial detection of hyperglycemia","volume":"58","author":"Yamamoto","year":"2019","journal-title":"Intern Med"},{"key":"10.1016\/j.beem.2022.101657_bib17","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1210\/jc.2018-00728","article-title":"Programmed cell death-1 inhibitor\u2013induced type 1 diabetes mellitus","volume":"103","author":"Clotman","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101657_bib18","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/j.jtho.2016.12.015","article-title":"Association of serum anti-GAD antibody and HLA haplotypes with type 1 diabetes mellitus triggered by nivolumab in patients with non-small cell lung cancer","volume":"12","author":"Usui","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.beem.2022.101657_bib19","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.2169\/internalmedicine.9518-17","article-title":"Fulminant type 1 diabetes mellitus accompanied by positive conversion of anti-insulin antibody after the administration of anti-CTLA-4 antibody following the discontinuation of anti-PD-1 antibody","volume":"57","author":"Shiba","year":"2018","journal-title":"Intern Med"},{"key":"10.1016\/j.beem.2022.101657_bib20","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/jdi.13099","article-title":"Anti-programmed death ligand 1 therapy-induced type 1 diabetes presenting with multiple islet-related autoantibodies","volume":"11","author":"Honoki","year":"2020","journal-title":"J\u00a0Diabetes Investig"},{"key":"10.1016\/j.beem.2022.101657_bib21","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00262-018-2203-3","article-title":"Fulminant onset of insulin-dependent diabetes with positive anti-GAD antibody titers during treatment with nivolumab in a patient with NSCLC","volume":"67","author":"Matsuura","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.beem.2022.101657_bib22","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1007\/s00125-009-1539-9","article-title":"Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset","volume":"52","author":"Kawabata","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.beem.2022.101657_bib23","first-page":"62","article-title":"Class II HLA genotype in fulminant type 1 diabetes: a nationwide survey with reference to glutamic acid decarboxylase antibodies","volume":"3","author":"Tsutsumi","year":"2012","journal-title":"J\u00a0Diabetes Investig. The Japan Diabetes Society Committee on Type"},{"key":"10.1016\/j.beem.2022.101657_bib24","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s13340-020-00466-2","article-title":"Fulminant type 1 diabetes: recent research progress and future prospects","volume":"11","author":"Imagawa","year":"2020","journal-title":"Diabetol Int"},{"key":"10.1016\/j.beem.2022.101657_bib25","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1620\/tjem.244.33","article-title":"Painless thyroiditis and fulminant type 1 diabetes mellitus in a patient treated with an immune checkpoint inhibitor, nivolumab","volume":"244","author":"Sakurai","year":"2018","journal-title":"Tohoku J Exp Med"},{"key":"10.1016\/j.beem.2022.101657_bib26","first-page":"521","article-title":"A\u00a0case of type 1 diabetes mellitus developed hypopituitarism at around the same time after treatment with Pembrolizumab","volume":"63","author":"Ueda","year":"2020","journal-title":"J\u00a0Jpn Diab Soc"},{"key":"10.1016\/j.beem.2022.101657_bib27","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s13340-020-00459-1","article-title":"Case of slowly progressive type 1 diabetes mellitus with drastically reduced insulin secretory capacity after immune checkpoint inhibitor treatment for advanced renal cell carcinoma","volume":"12","author":"Yamaguchi","year":"2021","journal-title":"Diabetol Int"},{"key":"10.1016\/j.beem.2022.101657_bib28","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.2337\/dc18-2518","article-title":"T-lymphocyte infiltration to islets in the pancreas of a patient who developed Type 1 diabetes after administration of immune checkpoint inhibitors","volume":"42","author":"Yoneda","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.beem.2022.101657_bib29","first-page":"711","article-title":"An autopsy report of fulminant type 1 diabetes mellitus that developed during anti-programmed cell death-1 treatment","volume":"63","author":"Mukaida","year":"2020","journal-title":"J\u00a0Jpn Diab Soc"},{"key":"10.1016\/j.beem.2022.101657_bib30","series-title":"Homepage from the Japan Diabetes Society. Recommendation for the development of type 1 diabetes related to Immune Checkpoint Inhibitors","year":"2022"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X22000446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X22000446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:58:56Z","timestamp":1761497936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X22000446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1521690X22000446"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2022.101657","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Type 1 diabetes related to immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2022.101657","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101657"}}